May 6, 2020 / 6:27 PM / a month ago

U.S. FDA approves Novartis' lung cancer treatment

May 6 (Reuters) - Novartis AG on Wednesday got U.S. approval for its drug Tabrecta, to treat patients with a form of lung cancer, according to the U.S. Food and Drug Administration's website.

The drug has been approved to treat non-small cell lung cancer that has spread to other parts of the body, the FDA said. (bit.ly/2YGybmg)

The drug got a priority review from the FDA in February. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below